Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 105 participants.

Also called NCT05365438

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05365438
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05365438. Randomized; single masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Condition
Dyslipidemias
Condition
Atherosclerosis
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Omega 3-Atorvastatin
Intervention (Drug)
Omega 3-Atorvastatin
Intervention (Drug)
Atorvastatin-Ezetimibe
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Korea United Pharm. Inc. (class: industry)

Record details

Record id
cardio:ct-nct05365438
Content hash
0552d099ad76d64af92f16c81a210280a1ac627cd67e8240a8b6a645f6c15004